FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients

被引:10
作者
Georgina Turcott, Jenny [1 ]
Onate-Ocana, Luis F. [2 ]
Soca-Chafre, Giovanny [3 ]
Ramirez-Tirado, Laura-Alejandra [3 ]
Flores-Estrada, Diana [1 ]
Lucia Zatarain-Barron, Zyanya [1 ]
Arrieta, Oscar [1 ]
机构
[1] Natl Canc Inst Mexico INCan, Thorac Oncol Unit, Mexico City, DF, Mexico
[2] Natl Canc Inst Mexico INCan, Div Surg, Clin Res Div, Mexico City, DF, Mexico
[3] Natl Canc Inst Mexico INCan, Expt Oncol Lab, Mexico City, DF, Mexico
来源
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 2019年 / 71卷 / 03期
关键词
QUALITY-OF-LIFE; NUTRITIONAL-STATUS; ASSOCIATION; VALIDATION; ANAMORELIN; PROGNOSIS; THERAPY; DISEASE; IMPACT;
D O I
10.1080/01635581.2018.1506488
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer (LC) has a high rate of anorexia, which negatively affects quality-of-life and prognosis; however prevalence values may vary as per diagnostic test. There is no standard for anorexia diagnosis, currently the anorexia cachexia scale (A/CS) has been proposed as a tool for diagnosing anorexia with a consensus cutoff value of <= 24, nonetheless a validated cutoff value is required. The A/CS was evaluated in advanced Non-Small Cell Lung Cancer (NSCLC) patients to establish a cutoff value. The appetite item from the QLQ-C30 questionnaire and survival served as a standard reference. The cutoff value was associated with clinical and nutritional characteristics along with quality-of-life. Three hundred and twelve (312) NSCLC patients were evaluated. The mean A/CS value was 31 +/- 9 and the identified cutoff value was 32.5 (sensitivity: 80.3% and specificity: 85%). The proportion of anorexia accurately diagnosed with the cutoff value of 24 was 26%, while with 32 it was 50%. The A/CS cutoff value of 32 was associated with clinical parameters, nutritional consumption, and quality-of-life, and independently associated with overall survival. A score of <= 32 in the A/CS is proposed for anorexia diagnosis in order to identify patients at risk of complications involving malnutrition related to LC.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 50 条
  • [31] PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER
    Hwang, Deok Won
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1075 - S1075
  • [32] Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer
    Harper, P
    SEMINARS IN ONCOLOGY, 2003, 30 (04) : 2 - 12
  • [33] Treatment of older patients with advanced non-small cell lung cancer: A challenge
    Decoster, Lore
    Schallier, Denis
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (04) : 528 - 533
  • [34] A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer
    Temel, Jennifer S.
    Greer, Joseph A.
    Goldberg, Sarah
    Vogel, Paula Downes
    Sullivan, Michael
    Pirl, William F.
    Lynch, Thomas J.
    Christiani, David C.
    Smith, Matthew R.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (05) : 595 - 601
  • [35] The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer
    Wu, Julie Tsu-Yu
    Corrigan, June
    Su, Chloe
    Dumontier, Clark
    La, Jennifer
    Khan, Aparjita
    Arya, Shipra
    Harris, Alex H. S.
    Backhus, Leah
    Das, Millie
    Do, Nhan V.
    Brophy, Mary T.
    Han, Summer S.
    Kelley, Michael
    Fillmore, Nathanael R.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (09)
  • [36] Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients
    Zhu Chihong
    Ling Yutian
    Wan Danying
    Jiang Ruibin
    Sheng Huaying
    Gu Linhui
    Feng Jianguo
    ONCOTARGET, 2017, 8 (28) : 45577 - 45584
  • [37] Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer
    Lee, Sookyung
    Eo, Wankyu
    Jeon, Hyeonjin
    Park, Sora
    Chae, Jean
    JOURNAL OF CANCER, 2017, 8 (15): : 2974 - 2983
  • [38] Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
    Zhong, Yuejiao
    Wei, Qiang
    Lu, You
    Tang, Xiuliang
    Wang, Zhongqiu
    Chen, Lingxiang
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6016 - 6022
  • [39] Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
    Ge, Xiangwei
    Zhang, Zhibo
    Zhang, Sujie
    Yuan, Fang
    Zhang, Fan
    Yan, Xiang
    Han, Xiao
    Ma, Junxun
    Wang, Lijie
    Tao, Haitao
    Li, Xiaoyan
    Zhi, Xiaoyu
    Huang, Zhiyue
    Hofman, Paul
    Prelaj, Arsela
    Banna, Giuseppe Luigi
    Mutti, Luciano
    Hu, Yi
    Wang, Jinliang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2391 - 2400
  • [40] Therapeutic options for elderly patients with advanced non-small cell lung cancer
    Avery, Eric J.
    Kessinger, Anne
    Ganti, Apar Kishor
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 340 - 344